OSTEOARTHRITIS, AND MUScULOSKELETAL DISORDERS. SPAIN, SEVILLE, APRIL 2-5, 2014

1. Papapoulos S., Lippuner K., Roux C., et al. Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the freedom extension. Osteoporosis Int. 2014; vol 25, Sup 2: OC21.

2. Thomas T., Cheung A.M., Shane E., et al. Changes in lumbar spine QCT, DXA and TBS following treatment with denosumab (dmab), alendronate (aln), or placebo (pbo) in postmenopausal women with low bone mass. Osteoporosis Int. 2014; vol 25, Sup 2: OC30.

3. Ferrari S., Adachi J.D., Lippuner K., et al. Further reduction in the nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the freedom extension.Osteoporosis Int. 2014; vol 25, Sup 2: OC39.

4. Ferrari S. Benefits-risk ratio of osteoporosis treatment: antiresorptives-bisphosphonates and denosumab. Osteoporosis Int. 2014; vol 25, Sup 2: SE9.

5. Libanati C., Ominsky M.S., Boyce R.W., et al. Progressive increases in hip bone mineral density (BMD) with denosumab treatment could be explained by continuous modeling-based bone formation. Osteoporosis Int. 2014; vol 25, Sup 2: P134.

6. Genant H.K., Keaveny T.M., Zapalowski C., et al. Clinical relevance of changes in hip bone parameters in response to denosumab vs placebo in postmenopausal women with osteoporosis №75 and >75 years old. Osteoporosis Int. 2014; vol 25, Sup 2: P135.